Related Experiment Video
Updated: Dec 23, 2025
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019
Zhe Zhu1, Ting Cai2, Lingyan Fan3
1Department of Blood Transfusion, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, PR China; Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, PR China.
Insights
High levels of interleukin-6 (IL-6), C-reactive protein (CRP), and hypertension are key indicators for assessing COVID-19 severity. These factors, particularly IL-6, show significant predictive value in risk models for severe coronavirus disease 2019.
Area of Science:
- Immunology
- Infectious Diseases
- Clinical Medicine
Background:
- Coronavirus disease 2019 (COVID-19) poses a significant global health challenge.
- Assessing disease severity is crucial for effective patient management and resource allocation.
- Immune-inflammatory markers are being investigated for their role in COVID-19 pathogenesis.
Purpose of the Study:
- To evaluate the clinical utility of immune-inflammatory markers in determining COVID-19 severity.
- To identify independent risk factors associated with severe outcomes in COVID-19 patients.
Main Methods:
- A cohort of 127 hospitalized COVID-19 patients was analyzed.
- Patients were categorized into non-severe and severe groups.
- Demographic, clinical, and laboratory data, including immune markers, were assessed for predictive value.
Main Results:
- Interleukin-6 (IL-6), C-reactive protein (CRP), and hypertension were identified as independent risk factors for severe COVID-19.
- A risk model incorporating IL-6, CRP, and hypertension demonstrated the highest predictive accuracy (highest AUROC).
- Elevated baseline IL-6 correlated with other inflammatory markers and disease progression.
Conclusions:
- High IL-6, CRP levels, and hypertension are significant predictors of COVID-19 severity.
- A risk model based on these factors offers robust predictability for severe disease.
- IL-6 is pivotal in COVID-19 severity and valuable for monitoring severe cases.
Objective:
To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19).
Methods:
127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value.
Results:
Of 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease.
Conclusion:
Our study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases.
Related Concept Videos
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:19Pericarditis II: Clinical Features and Diagnostic Tests